Hormone-receptor-positive breast cancer
Disease1 paper
- Humans1
Trial sponsors
Novartis Pharmaceuticals Corporation
Company1 trialPhase 2202 people
Company1 trialPhase 1/295 people
1 trialPhase 2393 people
Seoul National University Hospital
1 trialPhase 2238 people
1 trialPhase 2185 people
1 trialPhase 260 people
Rutgers, The State University of New Jersey
1 trialPhase 240 people
Latest
1medRxivHumansPreprint
Hormone therapy linked to lower breast cancer mortality
Compared with never-users, hormone therapy ever-users had adjusted hazard ratios, which compare event rates over time, of 0.72 for breast cancer death…Compared with never-users, hormone therapy ever-users had adjusted hazard ratios, which compare event rates over time, of 0.72 for breast cancer death and 1.17 for diagnosis.